期刊文献+

培美曲塞联合奥沙利铂或顺铂一线治疗晚期肺腺癌的临床研究 被引量:4

Clinical study on pemetrexed plus oxaliplatin or cisplatin as first-line chemotherapy for advanced lung adenocarcinoma
下载PDF
导出
摘要 目的比较培美曲塞联合顺铂和培美曲塞联合奥沙利铂一线治疗晚期肺腺癌的疗效和不良反应。方法选择经病理确诊的57例肺腺癌初治患者,随机分入PO组(培美曲塞500 mg/m2,第1天,奥沙利铂135 mg/m2,第1天,予以静脉滴注,每3周为1个疗程;n=29)和PC组(培美曲塞500 mg/m2,第1天,顺铂25 mg/m2,第1、2、3天,予以静脉滴注,每3周为1个疗程;n=28)。经两周期治疗后,评价两组疗效和不良反应。结果培美曲塞联合奥沙利铂组总反应率为37.9%,培美曲塞联合顺铂组为35.7%;培美曲塞联合奥沙利铂组临床获益率为72.4%,培美曲塞联合顺铂组为78.6%;培美曲塞联合奥沙利铂组无进展生存期为19周,培美曲塞联合顺铂组为22周;培美曲塞联合奥沙利铂组总生存期为41周,培美曲塞联合顺铂组为39周。两组比较,差异无统计学意义(P>0.05)。但培美曲塞联合奥沙利铂组患者3~4级呕吐发生率为3.4%,培美曲塞联合顺铂组为10.7%;培美曲塞联合奥沙利铂组患者3~4级中性粒细胞减少发生率为10.3%,培美曲塞联合顺铂组为21.4%,两组比较,差异有统计学意义(P<0.05)。结论使用培美曲塞联合奥沙利铂或者顺铂作为一线方案治疗晚期肺腺癌具有相同的疗效,但联合奥沙利铂具有更好的耐受性。 Objective To compare the efficacy and toxicity of pemetrexed plus oxaliplatin or cisplatin as the first-line chemotherapy for advanced lung adenocarcinoma.Methods 57 patients with advanced lung adenocarcinoma confirmed by pathologic examination without treatment were divided into two groups randomly.The PO group received pemetrexed(500 mg/m2 on 1d) and oxaliplatin(130 mg/m2 on 1 d) by intravenous infusion with 3 weeks as a treatment course(n=29).The PC group received pemetrexed(500 mg/m2 on 1 d) and cisplatin(25 mg/m2 on 1,2,3 d) by intravenous infusion with 3 weeks as a treatment course(n=28).The efficacy and toxicity were evaluated after two cycles of treatment.Results There were no significant difference in the overall response rate(37.9% vs 35.7%),clinical benefit rate(72.4% vs 78.6%),progress-free survival(19 weeks vs 22 weeks) and overall survival(41 weeks vs 39 weeks)between the PO group and PC group(P〉0.05).However,compared with the PC group,less patients in the the PO group experienced the grade 3 or 4 vomitting(3.4% vs 10.7%) and the grade 3 or 4 neutropenia(10.3% vs 21.4%),showing statistical difference between the two groups(P〈0.05).Conclusion Pemetrexed combined with oxaliplatin or cisplatin as the first-line chemotherapy regimens for advanced lung adenocarcinoma has similar efficacy,but pemetrexed combined with oxaliplati has better tolerability than pemetrexed combined with cisplatin.
作者 田述梅
出处 《现代医药卫生》 2012年第17期2570-2572,共3页 Journal of Modern Medicine & Health
关键词 肺肿瘤 药物疗法 抗肿瘤药 治疗应用 顺铂 治疗应用 培美曲塞 奥沙利铂 Lung neoplasms/drug therapy Antineoplastic agents/therapeutic use Cisplatin/therapeutic use Pemetrexed Oxaliplati
  • 相关文献

参考文献10

  • 1Li M, Zhang Q, Fu P, et al. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer:a meta-analysis of randomized controlled trials[J]. PLoS One, 2012,7 (5) : e37229. 被引量:1
  • 2Scagliotti GV, Parikh P, yon Pawel J, et al. Phase UI study comparing cis- platin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-.naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008,26 (21 ) : 3543-3551. 被引量:1
  • 3Virag P,Perde-Schrepler M, Fischer-Fodor E, et al. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cel- lular uptake in colorectal cancer cell lines[J/10L]. Antieancer Drugs ,2012 [2012-05-18].http ://www.nebi.nlm.nih.gov/pubmed. 被引量:1
  • 4Peterson P,Park K ,Fossella F,et al. Is pemetrexed more effective in ade- and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase -I trim of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) :P2-328[J]. J Thorac Onco1,2007,2(8) :S85 I. 被引量:1
  • 5Ciuleanu T, Brodowicz T,Zielinski C,et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non- small-cell lung cancer : a randomised, double-blind, phase 3 study[J]. Lancet ,2009,374 (9699) : 1432-1440. 被引量:1
  • 6Metro G,Chiari R, Mare M,et al. Carboplatin plus pemetrexed for plat- inum-pretreated ,advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation[J]. Cancer Chemother Pharmacol, 2011,68(6) :1405-1412. 被引量:1
  • 7Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatln in the first-line treatment of advanced nonsmall cell lung cancer[J]. Cancer,2005,104( 11 ) : 24zt9-2456. 被引量:1
  • 8Scagliotti GV,Parikh P, yon Pawel J, et al. Phase III study comparing cis- platin plus genacitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008,26 (21 ) : 3543-3551. 被引量:1
  • 9Gmnberg BH,Bremnes RM ,Flatten O ,et al. Phase III study by the Nor- wegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancerlJl. J Clin Oncol,2009, 27 (19):3217-3224. 被引量:1
  • 10Scagliotti GV ,Kortsik C ,Dark GG ,et al. Pemetrexed combined with ox- aliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer:a multicenter,randomized,phase 1I triM[J]. Clin Cancer Res, 2005,11 (2 Pt l ) : 690-696. 被引量:1

同被引文献26

  • 1Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Or- ganization for Research and Treatment of Cancer, National Can- cer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000,92 (3) : 205-216. 被引量:1
  • 2Buna PA. Chemotherapy for advanced non-small-cell lung cancer: who,what,when,why? [J]. J Clin Oncol,2002,20 (18 Suppl) :S23-33. 被引量:1
  • 3Scagliotti GV, Parikh P, yon Pawel J, et al. Phase Ⅲ study com- paring cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small- cell lung cancer[J]. J Clin Oncol, 2008,26 (21 ) :3543-3551. 被引量:1
  • 4Willingham W, Stafford EA, Reynolds SH, et al. Mechanism of eukaryotic protein synthesis inhibition by brusatol [J]. Biochim Biophys Acta, 1981,654(2) : 169-174. 被引量:1
  • 5Kigoshi S, Ito R. High levels of free fatty acids in lymphoid cells, with special reference to their cytotoxicity[J]. Experientia, 1973, 29(11 ) : 1408-1410. 被引量:1
  • 6NSCLC MetaAnalyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced nonsmallcell lung cancer: asystematic review and metaanalysis of individual patient data from 16 randomized controlled trials[J].J Clin Oncol.2008, 26(28):4617-4625. 被引量:1
  • 7AlSaleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced nonsmallcell lung cancer: metaanalysis of randomized controlled trials, with histology subgroup analysis[J]. Curr Oncol, 2012, 19(1): e9-e15. 被引量:1
  • 8Joerger M, Omlin A, Cerny T, et al. The role of pemetrexed in advanced non smallcell lung cancer: special focus on pharmacology and mechanism of action[J].Curr Drug Targets.2010, 11(1):37-47. 被引量:1
  • 9Mir O, BoudouRouquette P, Giroux J, et al. Pemetrexed, oxaliplatin and bevacizumab as firstline treatment in patients with stage Ⅳ nonsmall cell lung cancer[J].Lung Cancer.2012, 77(1):104-109. 被引量:1
  • 10Misset JL, Gamelin E, Campone M, et al. Phase Ⅰ and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors[J].Ann Oncol.2004, 15(7):1123-1129. 被引量:1

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部